| Date | Title | Description |
| 31.03.2025 | Opus Genetics Announces Financial Results for Full Year 2024 | Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases
Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance
New ... |
| 31.03.2025 | Opus Genetics Announces Financial Results for Full Year 2024 | Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases
Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance
New ... |
| 22.03.2025 | Opus Genetics Secures $20 Million in Funding to Propel Gene Therapy Development | In the ever-evolving landscape of biotechnology, Opus Genetics, Inc. has made a significant move. The company, based in Research Triangle Park, North Carolina, has announced a public offering and a concurrent private placement, collectively... |
| 21.03.2025 | Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million | RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal... |
| 21.03.2025 | Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million | Additional approximately $21 million tied to data release for the Company’s BEST1 program
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthal... |
| 03.12.2024 | Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 | FARMINGTON HILLS, Mich., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophth... |
| 12.11.2024 | Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update | In October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal diseases (IRDs)
The pro forma cash balance of the combined compa... |
| 12.11.2024 | Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies ... |
| 12.11.2024 | Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies ... |
